These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8612219)

  • 1. Closing in on human immunodeficiency virus-1.
    Mellors JW
    Nat Med; 1996 Mar; 2(3):274-5. PubMed ID: 8612219
    [No Abstract]   [Full Text] [Related]  

  • 2. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 3. Structural mechanisms of HIV drug resistance.
    Erickson JW; Burt SK
    Annu Rev Pharmacol Toxicol; 1996; 36():545-71. PubMed ID: 8725401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to overcome resistance of HIV-1 to HIV-1-specific reverse transcriptase inhibitors.
    De Clercq E
    AIDS; 1994 Jul; 8(7):1020-1. PubMed ID: 7524543
    [No Abstract]   [Full Text] [Related]  

  • 5. Qualitative study of drug resistance in retroviral protease using structural modeling and site-directed mutagenesis.
    Culberson JC; Bush BL; Sardana VV
    Methods Enzymol; 1994; 241():385-94. PubMed ID: 7854190
    [No Abstract]   [Full Text] [Related]  

  • 6. Human immunodeficiency virus. Protease uninhibited.
    Richman DD
    Nature; 1995 Apr; 374(6522):494. PubMed ID: 7700370
    [No Abstract]   [Full Text] [Related]  

  • 7. [Drugs active against retroviruses].
    Brun-Vézinet F; Descamps D
    Rev Prat; 1997 Mar; 47(6):631-8. PubMed ID: 9183937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors.
    Olomola TO; Klein R; Mautsa N; Sayed Y; Kaye PT
    Bioorg Med Chem; 2013 Apr; 21(7):1964-71. PubMed ID: 23415084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-resistance within the protease inhibitor class.
    Race E
    Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
    Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
    J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review.
    Erice A; Balfour HH
    Clin Infect Dis; 1994 Feb; 18(2):149-56. PubMed ID: 7512829
    [No Abstract]   [Full Text] [Related]  

  • 12. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase.
    Baldwin ET; Bhat TN; Liu B; Pattabiraman N; Erickson JW
    Nat Struct Biol; 1995 Mar; 2(3):244-9. PubMed ID: 7773792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of drug resistance mutations in B, non-B subtypes, and recombinant forms of human immunodeficiency virus type 1 in infected individuals in Spain (Galicia).
    Pérez-Alvarez L; Cuevas MT; Villahermosa ML; Pedreira JD; Manjón N; Herrero I; López-Calvo S; Delgado E; de Parga EV; Medrano L; Thomson MM; Taboada JA; Nájera R;
    J Hum Virol; 2001; 4(1):35-8. PubMed ID: 11213931
    [No Abstract]   [Full Text] [Related]  

  • 14. Sequencing antiretroviral drugs.
    Soriano V
    AIDS; 2001 Mar; 15(5):547-51. PubMed ID: 11316990
    [No Abstract]   [Full Text] [Related]  

  • 15. Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
    Skulnick HI; Johnson PD; Howe WJ; Tomich PK; Chong KT; Watenpaugh KD; Janakiraman MN; Dolak LA; McGrath JP; Lynn JC
    J Med Chem; 1995 Dec; 38(26):4968-71. PubMed ID: 8544171
    [No Abstract]   [Full Text] [Related]  

  • 16. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.
    Winters MA; Merigan TC
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2575-82. PubMed ID: 15980322
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV-1 drug resistance in newly infected individuals.
    Boden D; Hurley A; Zhang L; Cao Y; Guo Y; Jones E; Tsay J; Ip J; Farthing C; Limoli K; Parkin N; Markowitz M
    JAMA; 1999 Sep 22-29; 282(12):1135-41. PubMed ID: 10501116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.
    Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A
    J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
    Wainberg MA; Drosopoulos WC; Salomon H; Hsu M; Borkow G; Parniak M; Gu Z; Song Q; Manne J; Islam S; Castriota G; Prasad VR
    Science; 1996 Mar; 271(5253):1282-5. PubMed ID: 8638110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments of peptidomimetic HIV-1 protease inhibitors.
    Qiu X; Liu ZP
    Curr Med Chem; 2011; 18(29):4513-37. PubMed ID: 21864279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.